{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:32:49Z","timestamp":1788186769895,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011913","name":"Kaohsiung Veterans General Hospital","doi-asserted-by":"publisher","award":["SE22220A-1"],"award-info":[{"award-number":["SE22220A-1"]}],"id":[{"id":"10.13039\/501100011913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","heartrhythmjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.hrthm.2025.01.045","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:08:13Z","timestamp":1738973293000},"page":"1197-1209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness and safety of apixaban and warfarin in patients with new- onset atrial fibrillation after advanced chronic kidney disease or end-stage kidney disease"],"prefix":"10.1016","volume":"22","author":[{"given":"Ming-Ju","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6119-0587","authenticated-orcid":false,"given":"Shang-Feng","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2025.01.045_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2025.01.045_bib2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0735-1097(00)01107-4","article-title":"Epidemiology and natural history of atrial fibrillation: clinical implications","volume":"37","author":"Chugh","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2025.01.045_bib3","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.114.008201","article-title":"Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning","volume":"129","author":"Patel","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2025.01.045_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2007111207","article-title":"Dilemmas in the management of atrial fibrillation in chronic kidney disease","volume":"20","author":"Reinecke","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hrthm.2025.01.045_bib5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/j.ajkd.2013.02.381","article-title":"Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation","volume":"62","author":"Ng","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hrthm.2025.01.045_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2025.01.045_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/eurheartj\/ehu139","article-title":"Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study","volume":"36","author":"Friberg","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2025.01.045_bib8","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jacc.2006.11.045","article-title":"Trends in anticoagulation for atrial fibrillation in the US: an analysis of the national ambulatory medical care survey database","volume":"49","author":"Rowan","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2025.01.045_bib9","doi-asserted-by":"crossref","first-page":"c142","DOI":"10.1159\/000312877","article-title":"Warfarin therapy that results in an international normalization ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease","volume":"115","author":"Brodsky","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.hrthm.2025.01.045_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-214142","article-title":"Warfarin-induced calciphylaxis","volume":"2016","author":"Al-ani","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.hrthm.2025.01.045_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.amjmed.2013.08.033","article-title":"Warfarin, calciphylaxis, atrial fibrillation, and patients on dialysis: outlier subsets and practice guidelines","volume":"127","author":"Eiser","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.hrthm.2025.01.045_bib12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/europace\/euz358","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.hrthm.2025.01.045_bib13","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2025.01.045_bib14","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.jacc.2016.02.082","article-title":"Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF","volume":"67","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2025.01.045_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2018.05.005","article-title":"Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"94","author":"Wanner","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.hrthm.2025.01.045_bib16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2025.01.045_bib17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/medicina57050422","article-title":"Oral anticoagulant treatment in patients with atrial fibrillation and chronic kidney disease","volume":"57","author":"Stoica","year":"2021","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"10.1016\/j.hrthm.2025.01.045_bib18","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2025.01.045_bib19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000516280","article-title":"Incidence of uncommon clinical events in USA patients with dialysis-dependent and nondialysis-dependent chronic kidney disease: analysis of electronic health records from TriNetX","volume":"145","author":"Sultan","year":"2021","journal-title":"Nephron"},{"key":"10.1016\/j.hrthm.2025.01.045_bib20","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00392-021-01983-z","article-title":"Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation","volume":"111","author":"Ding","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.hrthm.2025.01.045_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106917","article-title":"Outcomes in patients with ischaemic stroke undergoing endovascular thrombectomy: impact of atrial fibrillation","volume":"32","author":"Alobaida","year":"2023","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.hrthm.2025.01.045_bib22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11739-022-03184-6","article-title":"Thoracic aortic aneurysm and atrial fibrillation: clinical associations with the risk of stroke from a global federated health network analysis","volume":"18","author":"Proietti","year":"2023","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.hrthm.2025.01.045_bib23","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.19102\/icrm.2018.091203","article-title":"Variability in the calculation of time in therapeutic range for the quality control measurement of warfarin","volume":"9","author":"Siddiqui","year":"2018","journal-title":"J Innov Card Rhythm Manag"},{"key":"10.1016\/j.hrthm.2025.01.045_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.amjcard.2015.10.065","article-title":"The quandary of oral anticoagulation in patients with atrial fibrillation and chronic kidney disease","volume":"117","author":"Schwartzenberg","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2025.01.045_bib25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2025.01.045_bib26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2025.01.045_bib27","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.hrthm.2025.01.045_bib28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2025.01.045_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10557-021-07144-8","article-title":"Effect of rivaroxaban or apixaban in atrial fibrillation patients with stage 4-5 chronic kidney disease or on dialysis","volume":"35","author":"Chen","year":"2021","journal-title":"Cardiovasc Drug Ther"},{"key":"10.1016\/j.hrthm.2025.01.045_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/rth2.12083","article-title":"Safety and effectiveness of apixaban compared to warfarin in dialysis patients","volume":"2","author":"Reed","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.hrthm.2025.01.045_bib31","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2215\/CJN.09470916","article-title":"Use of oral anticoagulation in the management of atrial fibrillation in patients with ESRD: verdict 2","volume":"11","author":"Herzog","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.hrthm.2025.01.045_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.847286","article-title":"Direct oral anticoagulants vs. warfarin in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis","volume":"9","author":"Elfar","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.hrthm.2025.01.045_bib33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11239-023-02945-0","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: a systematic review and meta-analysis of randomized controlled trials","volume":"57","author":"de","year":"2024","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.hrthm.2025.01.045_bib34","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2025.01.045_bib35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1053\/j.ajkd.2022.03.007","article-title":"Apixaban dosing patterns versus warfarin in patients with nonvalvular atrial fibrillation receiving dialysis: a retrospective cohort study","volume":"80","author":"Wetmore","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hrthm.2025.01.045_bib36","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/ndt\/gfr658","article-title":"A case-control study of calciphylaxis in Japanese end-stage renal disease patients","volume":"27","author":"Hayashi","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hrthm.2025.01.045_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2237","article-title":"Anticoagulation for stroke prevention in patients with atrial fibrillation and end-stage renal disease-first, do no harm","volume":"3","author":"Belley-Cote","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.hrthm.2025.01.045_bib38","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/pace.13331","article-title":"Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis","volume":"41","author":"Chokesuwattanaskul","year":"2018","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.01.045_bib39","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/jhm.12926","article-title":"Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: a national cohort study","volume":"17","author":"Ellenbogen","year":"2022","journal-title":"J Hosp Med"},{"key":"10.1016\/j.hrthm.2025.01.045_bib40","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/ejh.13599","article-title":"Safety of apixaban compared to warfarin in hemodialysis patients: do antiplatelets make a difference?","volume":"106","author":"Ionescu","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hrthm.2025.01.045_bib41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ipej.2021.04.002","article-title":"Safety and efficacy of apixaban versus warfarin in patients with atrial fibrillation or venous thromboembolism and end-stage renal disease on hemodialysis: a systematic review and meta-analysis","volume":"21","author":"Murtaza","year":"2021","journal-title":"Indian Pacing Electrophysiol J"},{"key":"10.1016\/j.hrthm.2025.01.045_bib42","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2215\/CJN.14021021","article-title":"Apixaban versus warfarin for treatment of venous thromboembolism in patients receiving long-term dialysis","volume":"17","author":"Wetmore","year":"2022","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527125001225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527125001225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T08:38:32Z","timestamp":1745915912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527125001225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1547527125001225"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2025.01.045","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of apixaban and warfarin in patients with new- onset atrial fibrillation after advanced chronic kidney disease or end-stage kidney disease","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2025.01.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Heart Rhythm Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}